Wei Zheng, Wei Yang, Qing-E Zhang, Xin-Hu Yang, Dong-Bin Cai, Jin-Qing Hu, Gabor S Ungvari, Chee H Ng, Marc De Hert, Yu-Ping Ning, Yu-Tao Xiang
Background: Metabolic syndrome in patients with schizophrenia is a major health concern. The efficacy and safety of adjunctive rosuvastatin in treating dyslipidemia were controversial. Aims: To assess the efficacy and safety of adjunctive rosuvastatin for dyslipidemia in patients with schizophrenia. Methods: We systematically searched for relevant controlled clinical trials from the following databases: PubMed, PsycINFO, Cochrane Library, China Knowledge Network, WanFang Database and Chinese Biomedical Database up to September 28, 2017...
February 25, 2018: Shanghai Archives of Psychiatry